CMS has finalized a rule to implement a series of proposals issued earlier this year impacting Medicare Advantage plans and Medicare Part D plan sponsors. The rules were rushed into effect to get them out before the contract year 2021 bid deadline in June.
While emerging conventional wisdom may state biopharmaceutical companies could see a boon as a result of the COVID-19 pandemic thanks to new treatment and vaccine opportunities, the sector may not come out on top.
Biopharmaceutical company AstraZeneca has received more than $1 billion in funding from BARDA for the development, production and delivery of Oxford University's vaccine for COVID-19.
Understood as a virtual army in the war against COVID-19, AI has vast stockpiles of potential weaponry with which to wage many a battle. That’s the good news.
Testing all residents and staff at the nation’s nursing homes just once would collectively cost $440 million, according to data from the American Health Care Association and National Center of Assisted Living (AHCA/NCAL).
COVID-19 isn’t only keeping patients home when they should be seeing their doctors. It’s also keeping clinical investigators from moving ahead with their research.